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DSUMMARY
X-linked myopathy with excessive autophagy
(XMEA) is a childhood-onset disease characterized
by progressive vacuolation and atrophy of skeletal
muscle. We show that XMEA is caused by hypomor-
phic alleles of the VMA21 gene, that VMA21 is the
diverged human ortholog of the yeast Vma21p
protein, and that like Vma21p it is an essential
assembly chaperone of the V-ATPase, the principal
mammalian proton pump complex. Decreased
VMA21 raises lysosomal pH, which reduces lyso-
somal degradative ability and blocks autophagy.
This reduces cellular free amino acids, which upregu-
lates the mTOR pathway and mTOR-dependent
macroautophagy, resulting in proliferation of large
and ineffective autolysosomes that engulf sections
of cytoplasm, merge together, and vacuolate the
cell. Our results uncover macroautophagic overcom-
pensation leading to cell vacuolation and tissue
atrophy as a mechanism of disease.
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TR INTRODUCTIONV-ATPases are ubiquitous in endomembrane systems of all cellsand are also present at the plasma membrane of specializedcells that secrete acid. They are proton pumps that acidify
lysosomes and regulate the pH of multiple cell systems,
including the secretory pathway and the endovesicular system,
which use gradated pH to accomplish stepwise modifications.
The V-ATPase is composed of 13 subunits organized into a trans-
membrane (V0) and a cytoplasmic (V1) sector and has a unique
rotary pumping mechanism (Figure S1 available online) (Forgac,
2007). In yeast, assembly of the V0 sector takes place in the
endoplasmic reticulum (ER), and a chief chaperone coordinating
the process is the Vma21p protein (Malkus et al., 2004).
V-ATPase subunits are highly conserved from yeast to man,
but the closest mammalian sequence to Vma21p has less than
22% identity and lacks a dilysine signal important in Vma21p
function (Malkus et al., 2004), making it unclear whether this pre-
dicted protein (LOC203547) is indeed the Vma21p ortholog and
whether V-ATPase biogenesis in mammals parallels that of
yeast. The V-ATPase is vital. To date, all disease-causing muta-
tions in V-ATPase subunits are in specialized subunit isoforms
conferring specialized functions to the V-ATPase (Forgac,Cell 137, 235–246, April 17, 2009 ª2009 Elsevier Inc. 235
2007), e.g., bone resorption by osteoclast plasma membrane
V-ATPases. There are no diseases with mutations in the ubiqui-
tous subunits common to all V-ATPases.
X-linked myopathy with excessive autophagy (XMEA; MIM
310440) (Kalimo et al., 1988) is a skeletal muscle disorder
inherited in recessive fashion, affecting boys and sparing carrier
females. Onset is in childhood, and patients exhibit weakness of
the proximal muscles of the lower extremities, progressing
slowly to involve other skeletal muscle groups over time. Other
organs including the heart and brain are clinically unaffected.
Pathological analysis of skeletal muscle biopsies shows no
inflammation, necrosis, or apoptosis. Instead, myofiber demise
occurs through a novel form of autophagic cell death. Forty to
eighty percent of fibers are diseased, exhibiting giant autophagic
vacuoles 2–10 mm in size encircling sections of cytoplasm
including organelles, proteins, etc. The vacuoles contain lyso-
somal hydrolases, yet they are unable to complete digestion of
their contents. Instead, they migrate to the myofiber surface,
fuse with the sarcolemma, and extrude their contents extracellu-
larly, forming a field of cell debris around the fiber (Figures S1 and
S2) (Chabrol et al., 2001; Kalimo et al., 1988; Minassian et al.,
2002; Villanova et al., 1995).
We show that LOC203547 is the human ortholog of Vma21p
and that hypomorphic mutations in its gene disrupt autophagy
and cause XMEA. XMEA represents an unusual genetic mecha-
nism of disease: a major housekeeping enzyme complex (the
V-ATPase) essential to multiple cell systems in all cells is down-
regulated to only a level affecting to a clinical extent the system
with highest dependence on it, autophagy, in the tissue with
highest reliance on autophagy, skeletal muscle.
RESULTS
Hypomorphic Mutations in the LOC203547 Gene
Cause XMEA
We previously mapped the XMEA gene to a 0.58 Mb region
of Xq28 containing four known genes and a fifth, LOC203547,
predicted on the basis of multiple expressed sequence tags
(ESTs) and mRNAs (Munteanu et al., 2008). We have now
sequenced exons and flanking intronic sequences of all five
genes in XMEA patients from 14 families and found sequence
changes in only LOC203547 (Figure 1A). These changes were
present in all patients, and in all families segregated with the
disease. To confirm that the changes are mutations, we
sequenced LOC203547 in over 450 chromosomes from unaf-
fected individuals, including for each mutation 100 chromo-
somes from ethnically matched controls, none of which had
any of the changes (Table S1).
LOC203547 has three exons, and a 4.7 Kb transcript
expressed in all tissues (Figures 1A and S3). The mutations
consist of six different single-nucleotide substitutions (Figures
1A and S4 and Table S1). The first two, c.54 27A/T and
c.54 27A/C, eliminate the A nucleotide predicted to define
the first intron’s splice branch point. The third, c.163 +4A/G,
removes the A in the +4 position after exon 2 that is required
for optimal U1 small nuclear RNA (snRNA) binding during
splicing. The fourth, c.164 7T/G, disrupts the polypyrimidine
tract in intron 2, which would reduce the U2AF splice factor
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A236 Cell 137, 235–246, April 17, 2009 ª2009 Elsevier Inc.binding efficiency. A fifth, c.272G/C, is in coding sequence
replacing a glycine with alanine, but it also abolishes a predicted
splice enhancer site. The sixth, c.*6A/G, is in the 30 untrans-
lated region (UTR).
Splice site mutations cause disease by generating abnormal
spliceforms or by decreasing mRNA quantity through reduced
splicing efficiency. We detected no splice variants, but quantita-
tive RT-PCR (qRT-PCR) in lymphoblasts and fibroblasts
revealed 32%–58% reduction in LOC203547 mRNA in all
patients, including those with the 30 UTR mutations (Figures 1B
and 1C). Western blots and immunocytochemistry showed that
LOC203547 is also reduced at the protein level (Figures 1D
and 1E). To confirm that these reductions are directly caused
by the LOC203547 mutations and are not secondary disease
effects, we created minigene constructs for each of the splice
site mutations (Figure S5) and expressed them in C2C12
myoblasts. In these experiments, the only difference between
patient and control minigenes is the one LOC203547 nucleotide
mutated in each patient. qRT-PCR showed >40% decrease in
LOC203547 minigene mRNA in patients versus controls (Figures
1F and 1G), confirming that the mutations that we identified are
the cause of the LOC203547 downregulation.
LOC203547 Is the Human Ortholog of the Yeast
V-ATPase Assembly Chaperone Vma21p
Toward determining whether LOC203547 is the human ortholog
of Vma21p, we first asked whether its downregulation in XMEA
affects the V-ATPase, and whether this effect is the same as
the previously characterized effect of Vma21p deficiency on
the V-ATPase in yeast. The yeast vma21 deletion mutant
(vma21D) has drastically reduced V-ATPases and V-ATPase
activity in organellar membranes, and defective growth. It also
exhibits increased V1 sector proteins in its cytosol, which occurs
because normally V1 subunits are produced in the cytosol and
added later on to the ER-assembled V0 sector. In vma21D, V0
assembly fails. As a result, V1 proteins can no longer find V0
matches and accumulate in the cytosol (Malkus et al., 2004).
We measured V-ATPase activity in the light membrane fraction
(includes all organelles) of XMEA patient lymphoblast extracts
and found that it is reduced to 12%–22% of normal
(Figure 2A). In fibroblasts, V-ATPase activity was reduced to
11%–13% of normal, and in fresh-frozen muscle biopsies to
21%–33% of normal (Figure 2B). We next assessed the amount
of V-ATPases in the light membrane fractions by performing
immunoprecipitation and western blot experiments with anti-
bodies against several V0 and V1 components, and we found
them all reduced in patients (Figures 2C and 2D), indicating
that the decreased V-ATPase activity was due to decreased
numbers of organellar V-ATPases, which we confirmed by
directly counting V-ATPases on intact organelle membranes of
intact cells using immunogold electron microscopy (Figures 2E
and 2F). Western blots of cytosolic and light membrane fractions
showed that V1 subunits were increased in patient cytosols by an
amount similar to the amount by which they were decreased
from their organellar membranes (Figure 2D), indicating that
the decrease in V-ATPases is due to decreased formation of V0
complexes.
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Figure 1. LOC203547 Mutations and Their Effects
(A) The LOC203547 gene has three exons (open rectangles). The six mutations are named and their positions relative to the exons are depicted by bullets.
The LOC203547 protein has two predicted transmembrane domains (gray rectangles).
(B) LOC203547 RT-PCR in patient and control lymphoblasts.
(C) LOC203547 quantitative RT-PCR in lymphoblasts measured as a ratio to b-actin.
(D) LOC203547 protein in patient and control lymphoblasts by western blot.
(E) LOC203547 protein in patient and control fibroblasts by immunofluorescence light microscopy.
(F) RT-PCR of four LOC203547 minigene constructs after transfection into C2C12 myoblasts; the PRDM8 gene cotransfected as transfection efficiency control;
endogenous GAPDH expression used as control of starting mRNA amount.
(G) Quantitative RT-PCR of above minigenes relative to b-actin.
Error bars in (C) and (G) represent the mean ± standard deviation of three independent experiments.
ET
RA
CT
EDNext, we showed that LOC203547 directly interacts, within
membranes, with V0. Immunoprecipitation of LOC203547 from
light membrane fractions of control and patient cells after cross-linking and use of detergent C12E9 (which maintains lipid bilayer
protein complex integrity) coprecipitated the V0 complex
(Figures 3A and 3B). In the absence of crosslinking and C12E9,Cell 137, 235–246, April 17, 2009 ª2009 Elsevier Inc. 237
only V0 subunit c
00, and not other subunits, coprecipitated with
LOC203547 (Figure 3C), indicating that the interaction of
LOC203547 with V0 is via subunit c
00.
Finally, we asked whether LOC203547 can complement
vma21D. The vma21D yeast strain is characterized by a well-
defined set of growth defects including stunted growth on
complete media, and lack of growth on media with nonferment-
able carbon sources or with elevated pH or calcium (Malkus
et al., 2004). We cultured vma21D, LOC203547-transformed
vma21D, and wild-type yeast for 3 days in YP-glycerol (pH 5.5;
glycerol as carbon source), YPD (pH 7.5; elevated pH), and
YPD (pH 5.5) with 10 mM CaCl2. Vma21D showed characteristic
negligible growth, while LOC203547-transformed vma21D grew
proficiently, and equally to the wild-type, on all three media
(Figure 3D), showing that LOC203547 fully rescues vma21D.
Collectively, results in this section establish that LOC203547 is
the human ortholog of Vma21p. LOC203547 is named VMA21 in
the remainder of this paper.
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B Figure 2. Defective V-ATPase Activity and Assembly
in XMEA
(A and B) V-ATPase activity in lymphoblast and skeletal
muscle light membrane fractions, respectively. Error bars
represent the mean ± standard deviation of three independent
experiments.
(C) Immunoprecipitation, with anti-subunit ‘‘a’’ antibody, of
protein samples in light membrane fractions of lymphoblasts
under nondenaturing conditions with C12E9 detergent and
DTSSP crosslinking. Western blotting with the same antibody
detects the fully assembled V0 complex (250 kD), of which
subunit ‘‘a’’ is a part, and also free subunit ‘‘a’’ in the
membrane not bound to the complex (116 kD). In patients,
there are less V0 complexes. There is also decreased free
subunit ‘‘a,’’ because subunit ‘‘a’’ molecules not finding
binding partners are rapidly degraded (Malkus et al., 2004).
Anti-HA antibody was used as immunoprecipitation control.
(D) V1 subunit E in patients is decreased from light membrane
fractions (Mem) and increased in the cytosolic fraction (Cyt).
Band intensities in patients were as follows: c.6*A/G,
0.32 ± 0.14 (Mem) and 1.23 ± 0.24 (Cyt); c.272G/C, 0.44 ±
0.04 (Mem) and 1.36 ± 0.17 (Cyt); c.164-7T/G, 0.27 ± 0.03
(Mem) and 1.42 ± 0.11 (Cyt).
(E and F) Representative electron micrographs of neutrophils
from normal (E) and an XMEA case (F) immunogold labeled
against subunit ‘‘a.’’ In the XMEA patient, gold particle density
is reduced from the plasma membrane and from the
membranes of neutrophil phagosomes; the scale bar
represents 0.5 mm. Actual mean counts from 150 neutrophils
from three controls (50 cells per control) and 100 neutrophils
from two patients (50 cells per patient) were, in particles/
linear mm, as follows: control plasma membrane, 2.7 ± 0.5;
patient plasma membrane, 0.4 ± 0.1; control phagosome
membrane, 4.3 ± 0.75; patient phagosome membrane,
1.25 ± 0.06; significance < 0.001 (student’s t test).
The Subcellular Stations of VMA21 Diverge
from Those of Vma21p
In yeast, Vma21p first interacts in the ER
membrane with the V0 subunit c
0. This initiates
a stepwise assembly of the other V0 components,
and presence of Vma21p is necessary throughout
the process. Once V0 is formed, Vma21p accompanies it on
COPII vesicles to the Golgi apparatus, and V1 subunits are added
to complete the V-ATPase (Malkus et al., 2004; Ochotny et al.,
2006). Vma21p is retargeted by its carboxy-terminal dilysine
signal to the ER, while each V-ATPase is directed to its particular
destination on the basis of which isoform of the V0 ‘‘a’’ subunit
was incorporated during V0 assembly (Malkus et al., 2004). To
determine the subcellular locations in which mammalian VMA21
acts, we stained C2C12 myoblasts and COS7 cells with VMA21
and organelle-specific antibodies. VMA21 localizes in the ER,
and not in mitochondria, peroxisomes, or lysosomes. It is not
present in Golgi or trans-Golgi networks. However, it does
localize in the ER-Golgi intermediate compartment (ERGIC)
and in COPII vesicles (Figure 4). VMA21 lacks a dilysine ER return
signal. Consistent with this, VMA21 does not localize on COPI,
the ER return vesicle (Figure 4A). In summary, VMA21 follows
part of the route of Vma21p, traveling from ER to ERGIC but
not beyond, and not back to ER, at least not via COPI vesicles.
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Figure 3. LOC203547 Interacts with the V0
Complex via c00 and Rescues Yeast vma21D
(A) LOC203547 coprecipitates the V0 sector of the
V-ATPase under nondenaturing conditions.
Proteins from C2C12 cells solubilized under non-
denaturing conditions in the presence of C12E9
detergent and DTSSP crosslinking were immuno-
precipitated with LOC203547 antibody and run on
SDS-PAGE. Under these conditions, western blot
with antibody against subunit ‘‘a’’ detects the
250 kD V0 complex, encompassing all compo-
nents of the complex including ‘‘a’’; no 116 kD
band corresponding to subunit ‘‘a’’ when it is not
bound to the complex is detected, because
LOC203547 does not interact directly with ‘‘a’’
and can therefore not bring it down except as
part of the complex. Subunit ‘‘d,’’ which is part of
V0 but which unlike subunit ‘‘a’’ is loosely bound
to the complex, is the only component that
becomes partly separated from the complex as
the complex runs in SDS-PAGE.
(B) In the presence of C12E9, and absence of
crosslinking, immunoprecipitation with
LOC203547 antibody and western blotting with
anti-subunit ‘‘a’’ antibody detects the 250 kD V0
complex. Under this condition, i.e., absence of
crosslinking, SDS-PAGE separates some of
subunit ‘‘a’’ from the complex, which is now seen
as a separate 116 kD band.
(C) Under full denaturing conditions, i.e., in the
absence of C12E9 and DTSSP crosslinking,
immunoprecipitation with LOC203547 antibody
and western blot with an antibody that recognizes
subunits c and c00 detects only the 21 kD c00 subunit
and does not show any 250 kD (V0) band; staining
with other subunit antibodies does not reveal any
other coimmunoprecipitated band (data not
shown). These results indicate that subunit c00 is
the direct interacting partner of LOC203547.
(D) Comparison of growth patterns of yeast strains
BY4741 (wild-type), vma21D, LOC203547-
transformed vma21D, and controls. Successive
dilutions (101–104) of synchronously grown
cultures of each strain plated in three different
growth media. LOC203547 rescues the vma21D
growth defect.TR
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DDecreased, Increased, and Excessive Autophagy
in XMEA
Autophagy is the degradation of long-lived proteins and other
cell components. It is composed of three processes with
a common final stage, digestion at low pH by lysosomal hydro-
lases. In chaperone-mediated autophagy, proteins are taken
into the lysosome via receptors. In microautophagy, they are
engulfed by the lysosome. In macroautophagy, an isolation
membrane forms in the cytoplasm, surrounds targeted proteins
and other constituents, and fuses with lysosomes. The transi-
tional structure prior to merger with lysosomes is called the
autophagosome, and the final organelle the autolysosome.
Macroautophagy is the largest contributor to autophagy and is
the system that expands to compensate for insufficiencies in
the nonmacroautophagic processes, or to meet increased auto-
phagic demands such as during starvation (Martinez-Vicente
et al., 2008; Mizushima et al., 2002).
RE
On the basis of our finding of decreased V-ATPase activity in
XMEA, we predicted that XMEA cells have increased lysosomal
pH and a resultant partial block in the common final degradative
stage of autophagy. To test this, we first measured lysosomal
pH. We incubated fibroblasts with Oregon green dextran over-
night, during which the dextran is endocytosed to the lysosome,
where it fluoresces with an intensity proportional to pH and emits
two wavelengths around an isobestic point, i.e., fluorescence
intensity at one wavelength is inversely proportional to the inten-
sity at the other and their ratio corrects for focal plane artifacts
(Figure S6) (Paroutis et al., 2004). pH of patient lysosomes was
0.5 units higher, i.e., three times less [H+], than that of controls
(Figure 5A). Next, we measured autophagy by quantifying the
degradation of long-lived proteins. We cultured lymphoblasts
and fibroblasts for 48 hr with radioactive cysteine and methio-
nine. After washing, we chased protein degradation by
measuring the trichloroacetic acid (TCA)-soluble fraction of totalCell 137, 235–246, April 17, 2009 ª2009 Elsevier Inc. 239
radioactivity for 72 hr. Three types of chase media were used to
allow calculation of total autophagy, macroautophagy, and non-
macroautophagy: routine media, media with lysosomal protease
inhibitors (NH4Cl and leupeptin), and media containing 3-methyl
adenine, a specific macroautophagy inhibitor. We found that in
controls and patients, approximately half of long-lived protein
degradation was macroautophagic and half was through non-
macroautophagy, that total long-lived protein degradation in
patients was 25 to 50% lower than that in controls, and that
this reduction in autophagic flux was due approximately equally
to reductions in macro and nonmacroautophagies (Figures 5B
and 5C). In separate experiments, proteolysis of short-lived
proteins, which is largely proteasomal and nonlysosomal, was
unaffected (data not shown).
We reasoned that the block in autophagy should induce an
upregulation of macroautophagy. Beclin-1 is a pivotal early
component of the macroautophagy pathway. Its increased
A
B
Figure 4. Intracellular Localization of VMA21
(A) C2C12 cells were treated with VMA21 antibody and
costained with antibodies against compartment-specific
markers. Yellow fluorescence indicates colocalization.
VMA21 localizes at the endoplasmic reticulum (ER), at the
ER-Golgi intermediate compartment (ERGIC), and on COPII
vesicles.
(B) Electron micrograph of VMA21 immunogold-labeled
ultrathin cryosection of the same cells. Arrows, ER and ER
terminal cisternae; arrowhead, a mitochondrion. The scale
bar represents 0.25 mm.
amount and interaction with the class III PI3 kinase
hVps34 activate and upregulate the pathway (Cao
and Klionsky, 2007). LC3 is a cytosolic protein
that upon activation of macroautophagy converts
from its LC3-I (18 kD) to its LC3-II (16 kD) form to
function in the isolation membrane that forms the
autophagosome (Mizushima et al., 2002). Western
blot and immunoprecipitation studies in lympho-
blasts and fibroblasts showed major increase in
beclin-1, beclin-1-hVps34 interaction, and LC3-II
in XMEA patients (Figure 5D). LC3 was also
increased at the transcriptional level, 2-fold. The
mRNA of a second early macroautophagy gene
tested, ATG12, was increased 10-fold (Figure 5E).
These results confirm that macroautophagy is
upregulated in XMEA. We next tested the phos-
phorylation status of the p70S6 kinase and found
it to be dephosphorylated (Figure 5D). This indi-
cates that of the several pathways to autophagic
upregulation, the mTOR pathway is activated
(Cao and Klionsky, 2007). This pathway is princi-
pally activated by reduced levels of cellular amino
acids. We measured the concentration of free
amino acids in XMEA cells and found it to be
50% lower than that in controls (Figure 5F).
Autolysosomes are evanescent structures that
rapidly degrade their contents, and few are
observed in normal cells at any one time. We asked
whether in XMEA the upregulation of macroautophagy, coupled
with delayed degradation of autolysosomal contents, results in
increased autolysosomes. Electron and immunofluorescence
microscopy showed in all XMEA lymphoblasts and fibroblasts,
as well as in their blood leukocytes and platelets, a proliferation
of normal autolysosomes (Figures 6A and 6B). Ninety percent of
these cells were otherwise morphologically normal. However, in
10%, the numerous autolysosomes were observed merging one
with the other, forming giant vacuoles identical to the disease-
defining autophagic vacuolation of XMEA skeletal muscle
(Figures 6C–6E). These observations show that XMEA cells other
than muscle have the same autophagic vacuolation as muscle
cells, though in a smaller proportion (10% versus 40%–80%).
They also show a continuum from upregulated autophagy to
proliferation of autolysosomes to autophagic vacuolation.
Finally, we aimed to determine whether VMA21 mutations
cause the above succession of events through their
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Figure 5. Increased Lysosomal pH,
Decreased Protein Degradation, and
Increased Macroautophagy
(A) Spread of lysosomal pH values in patient and
control fibroblasts. Eleven ‘‘B’’ symbols per
subject are displayed, each the mean of pH
measurements of ten lysosomes per cell. Patient
lysosome pH values range from 5.0 to 5.2, and
control values from 4.4 to 4.7.
(B) Chase of lysosome-dependent long-lived
protein degradation in lymphoblasts. In this and
next panel, chase media contained MG-132 to
eliminate proteasomal contribution. Also, any other
nonlysosomal proteolysis—measured as protein
degradation in cells cultured in parallel in media
with NH4Cl/leupeptin—was subtracted from total
proteolysis to obtain the data shown. Nonlysoso-
mal proteolysis was negligible, <3% of lysosomal,
and unvarying. P1, P2, etc. are different XMEA
patients.
(C) I: Thirty-six hour time points from (B). II: Cells
cultured with the specific macroautophagy inhib-
itor 3MA; measures the nonmacroautophagic
portion of lysosome-dependent protelysis. III:
Difference between I and II, i.e., between total lyso-
some-dependent proteolysis and its nonmacroau-
tophagic portion; measures the macroautophagic
portion of total lysosome-dependent proteolysis.
Error bars represent the mean ± standard deviation
of three independent repeats.
(D) Macroautophagic upregulation in XMEA cells
and low-dose leupeptin treated non-XMEA cells.
(a) Coimmunoprecipitation of hVps34-beclin-1
interaction complexes with the beclin-1 mono-
clonal antibody in control and patient cells was
performed. Immunoprecipitates were run on
SDS-PAGE, and western blot with polyclonal-
rabbit anti-beclin-1 and hvps34 antibody shows
increase in beclin-1 and hvps34-beclin-1
complexes in patients and leupeptin-treated cells.
GAPDH was used as loading control and anti-HA
antibody as immunoprecipitation control. (b) Phos-
phorylation status of the p70S6 kinase was deter-
mined with phospho-specific and total p70S6
kinase antibodies; p70S6 kinase is less phosphor-
ylated in patients and leupeptin-treated cells. Total
p70S6 kinase levels remain similar in patients,
leupeptin-treated cells, and controls. (c) An
immunoblot of LC3 is shown; total LC3 and the
LC3-II isoform are increased in patients and
leupeptin-treated cells.
(E) Quantitative RT-PCR of the LC3B gene shows 1.5- to 2-fold increased expression in patients, and of the ATG12 gene a 10-fold increase. Expression of the
b-actin gene was used as control. Error bars represent the mean ± standard deviation from three independent experiments performed in triplicate.
(F) Quantitation of intracellular free aminoacids. White bars, lymphoblasts; gray bars, fibroblasts; C, normal cells; S, normal cells in starvation condition (Hanks
balanced salt solution for four hours). Note that XMEA cells maintain themselves at even lower free amino acid concentration than do amino acid-starved normal
cells. Error bars represent the mean ± standard error on triplicate readings.RE
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anism, i.e., we asked whether decreased autophagy by 25% to
50% alone elicits macroautophagy and autophagic vacuolation.
Leupeptin is a pH-independent inhibitor of lysosomal hydro-
lases. First, we identified 30 mM as the leupeptin concentration
needed to decrease long-lived protein degradation by 37%
(Figure S7). Lymphoblasts and fibroblasts from normal subjects
incubated with this concentration of leupeptin exhibitedmTOR-dependent upregulation of macroautophagy autolyso-
some proliferation, mergers of autolysosomes, and autophagic
vacuolation (Figures 5D and 6F), identical to XMEA.
Restoring VMA21 mRNA Levels Corrects
the XMEA Autophagic Disturbance
As final proof that decreased VMA21 is the cause of the autopha-
gic disturbance in XMEA, we raised the levels of VMA21mRNA inCell 137, 235–246, April 17, 2009 ª2009 Elsevier Inc. 241
XMEA fibroblasts by retrovirus infection and stable expression of
VMA21. Cells treated in this fashion exhibited normalization of
V-ATPase assembly and activity, lysosomal pH, long-lived
protein degradation, intracellular amino acid levels, beclin-1
levels, beclin-1-hVps34 interaction, and LC3 isoforms. Autolyso-
somes and autophagic vacuoles were no longer present and
cells returned to normal morphology (Figures 7A–7H).
Not All V-ATPase-Dependent Functions Are Affected
in XMEA
Multiple cell systems other than autophagy require V-ATPases,
none of which appears to be affected to a clinical extent in our
patients. We studied one of these systems, the maturation of
A
C
E F
D
B
Figure 6. Morphological Features of XMEA Fibroblasts
(A) Fibroblast from an unaffected individual. The scale bar represents 2 mm.
(B) Representative example of the most common appearance in patient
fibroblasts. An extensive number of autolysosomes distributed throughout
the cell. The scale bar represents 2 mm.
(C) Autolysosomes in a fibroblast from an affected individual merging to form
autophagic vacuoles. The scale bar represents 2 mm.
(D) Higher power of (C). The scale bar represents 0.5 mm.
(E) Extreme example of giant autophagic vacuolation in a fibroblast from an
affected patient. The scale bar represents 0.5 mm.
(F) Representative non-XMEA normal fibroblast treated with leupeptin exhibits
the morphological characteristics of XMEA. The scale bar represents 0.5 mm.RE
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successively lower pH. We examined hexosaminidases A and
B and cathepsin D in XMEA fibroblasts and found the matura-
tions of all three to be identical to controls (Figures S8 and S9).
DISCUSSION
XMEA mutations are hypomorphic alleles that reduce the
amount of VMA21, in most cases by decreasing mRNA splicing
efficiency. Only skeletal muscle is clinically affected, and only in
males. Female carriers are unaffected, likely because muscle is
a syncytium and half of the nuclei will produce normal amounts
of VMA21 mRNA. We show that VMA21 is the human ortholog
of the yeast V-ATPase chaperone Vma21p and that reduced
VMA21 results in misassembly of the V-ATPase, decreased
numbers of V-ATPases, and reduced cellular V-ATPase activity
to 10%–30% of normal.
Several other genetic diseases affecting V-ATPases have
been described. In all of these diseases, mutations affect
specific V-ATPases in particular cellular locations and are loss-
of-function mutations that completely eliminate the particular
V-ATPase. For example, mutations in the gene encoding the
a2 isoform of subunit ‘‘a’’ affect certain Golgi and early endo-
some V-ATPases in certain tissues, but not lysosomal or other
V-ATPases (causing developmental delay with wrinkled skin;
Kornak et al. [2008]). Mutations in a3 affect only V-ATPases on
osteoclast plasma membranes (causing osteopetrosis; Frattini
et al. [2000]). Mutations in a4 affect only renal and inner ear
plasma membrane V-ATPases (causing renal tubular acidosis
and deafness; Karet et al. [1999]). To our knowledge, XMEA is
the first disease in which total, not local, cellular V-ATPase
activity is affected. On the other hand, XMEA mutations do not
completely eliminate V-ATPase activity. XMEA patients do not
exhibit neurodevelopmental delay or clinically manifest skin
and bone abnormalities, acidosis, or hearing loss, indicating
that for the specialized a2-, a3-, and a4-containing V-ATPases
the reduced V-ATPase assembly in XMEA does not reach
a clinical threshold.
The reduced V-ATPase activity in XMEA results in a rise in
lysosomal pH from 4.7 to 5.2. Maturations of three lysosomal
enzymes tested are not affected. Their pH-dependent modifica-
tions are normal, and the final enzymes have normal activities
in vitro. In vivo, though, these enzymes are expected to have
lowered activity in patient lysosomes because of their raised
pH. Hexosaminidase, for example, is known to be 50% less
active at pH 5.2 than at pH 4.7 (Sharma et al., 2001). Not surpris-
ingly, this degree of hexosaminidase downregulation is tolerated
by XMEA patients who, like Tay-Sachs disease carriers who also
have 50% reduced hexosaminidase, do not have Tay-Sachs
symptoms. Other individual lysosomal enzymes are likely simi-
larly subclinically downregulated.
Autophagy, the collective activity of lysosomal enzymes
involved in the degradation of long-lived proteins, also is
reduced. The extent of this reduction in patient cell lines is
certainly greater than the 50% we recorded, because, as we
showed, it is coupled with a compensatory upregulation of mac-
roautophagy, with which cells achieve the 50% level. The
outcomes of reduced autophagy are reduced recycling of
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Figure 7. Restoring VMA21 mRNA Levels Corrects the XMEA Autophagic Disturbance
(A) HIV-mediated expression of VMA21 in patient fibroblasts (Patient-VMA21) as detected by western blot and immunocytochemistry.
(B) Rescue of V-ATPase assembly. M, membrane fraction; C, cytosolic fraction.
(C) Rescue of V-ATPase activity. Patient fb-neo, patient cells transfected with vector alone.
(D) Rescue of proteolysis.
(E) Correction of LC3.
(F) Normalization of beclin and hVps34-beclin-1 interaction; anti-HA antibody immunoprecipitation control.
(G) Correction of intracellular free amino acid level.
(H) Normalization of cellular morphology and disappearance of autophagic vacuolation. The scale bar represents 0.5 mm.
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defective and unneeded proteins, and reduced generation of
amino acids through this recycling. The cell can ill afford to fully
replace the amino acid shortfall with extrinsic amino acids from
culture medium or nutrition, because continual reliance on
external instead of recycled sources would result in continuing
net surpluses and ever-increasing accumulations of unneeded
proteins, which would increasingly tax already strained autoph-
agy. The cell therefore needs to find a new homeostasis, with
reduced cytoplasmic free amino acids, which we show is the
case in XMEA. Reduction of amino acids is the most potent
inducer of macroautophagy, through inhibition of the mTOR
kinase. mTOR reciprocally regulates macroautophagy and
protein synthesis. Inhibited mTOR dephosphorylates the
p70S6 kinase (as is the case in XMEA, Figure 5D), which reduces
protein synthesis, and expands macroautophagy through
enhanced beclin-1-hVps34 binding (Figure 5D) (Cao and Klion-
sky, 2007).
Increased macroautophagy means increased formation of
autolysosomes, but in XMEA each new autolysosome formed
faces a degradative block and is slow to progress and disappear.
Increased formation coupled with delayed progression results in
vast numbers of autolysosomes, in some cells fusing together
and forming giant autophagic vacuoles and autophagic vacuola-
tion identical to the disease in muscle that gives XMEA its name,
‘‘excessive autophagy.’’ The percent of cells in patient cell lines
and blood cells that are thus diseased, i.e., vacuolated, is10%.
The remaining 90%, except for the increased number of autoly-
sosomes, show no pathological changes. This indicates that in
90% of cells, the autophagic block is compensated by the
increased macroautophagy, but that this compensation is
precarious, with some cells, 10%, transitioning into autophagic
vacuolation. In skeletal muscle, the percent vacuolated cells is
much greater, 40% to 80%, which may explain why clinical
symptoms are present only in this tissue.
So far, we posited that the autophagic block is a consequence
of decreased V-ATPase activity. The possibility exists that it is
instead caused by some other effect of the VMA21 mutations
unrelated to their effect on the V-ATPase. This is ruled out by
the following. Bafilomycin is a specific inhibitor of the V-ATPase.
At concentrations above 10 nM, it completely inhibits V-ATPase
activity. Between 0.3 and 10 nM, it reduces V-ATPase activity to
10% to 40% of normal (Drose and Altendorf, 1997), similar to the
V-ATPase activity in XMEA. In the literature are several reports in
which, as controls for other experiments, cells of various types
were treated with these low concentrations of bafilomycin. This
resulted in decreased autophagy, mTOR-dependent activation
of macroautophagy, and autolysosome proliferation and auto-
phagic vacuolation (Ostenfeld et al., 2008; Shacka et al., 2006),
which upon review are identical to what we observe in XMEA.
V-ATPase block therefore has the same autophagic outcome
as VMA21 mutations, confirming that the mutations cause the
autophagic defect via their effect on the V-ATPase. The literature
also substantiates that decreased V-ATPase causes the auto-
phagic block through raising lysosomal pH, and not through
some alternate mechanism. Chloroquine and siramesine are
agents that accumulate in lysosomes, raise lysosomal pH, block
autophagy, and lead to mTOR-dependent macroautophagy and
autophagic vacuolation (Ostenfeld et al., 2008; Shacka et al.,
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antimalarial and antirheumatic agent. Prolonged exposure to
chloroquine causes an iatrogenic disease affecting only skeletal
muscle clinically, despite the fact that lysosomes of all tissues
are affected. This disease is an autophagic vacuolar myopathy
that is so similar to XMEA that it is its main pathological differen-
tial diagnosis (Kalimo et al., 1988; Minassian et al., 2002; Stauber
et al., 1981). The similarity between the effect on autophagy of
decreased V-ATPase, choloroquine, and siramesine, and
between XMEA and chloroquine myopathy, indicates that the
autophagic block caused by decreased V-ATPase is through
raising lysosomal pH. Finally, the autophagic block is the cause
of the macroautophagic upregulation and autophagic vacuola-
tion, as demonstrated in this study by blocking the last stage
of autophagy, through direct inhibition of lysosomal proteases
(to the same degree as in XMEA) and obtaining the same
mTOR-dependent macroautophagic upregulation and disease-
defining autophagic vacuolation as in XMEA.
Apart from chloroquine myopathy, the differential diagnosis of
XMEA includes one disease with known cause (Danon disease;
LAMP2 deficiency) (Nishino et al., 2000). LAMP2 participates in
chaperone-mediated autophagy, lysosome biogenesis, lyso-
some-autophagosome fusion, and lysosome locomotion along
microtubule tracts toward phagosomes (Malicdan et al., 2008).
Defects in any or all of these could reduce autophagy and
underlie the vacuolation. In fact, in the mouse model of this
disease, organs with reduced autophagy exhibit the autophagic
vacuolation (Tanaka et al., 2000).
Why muscle is principally affected in Danon disease, chloro-
quine myopathy, and XMEA is not known. In XMEA, this is not
due to less muscle V-ATPase activity, as we found no difference
in V-ATPase activity between muscle and other cells. We
theorize that the expanded vacuolation in muscle is due to a
particularity of macroautophagy in this tissue, namely a vastly
greater macroautophagic response to decreased amino acids
compared to other tissues, the purpose of which is to break itself
down to supply amino acids to other organs (Mizushima et al.,
2004; Scornik et al., 1997). This is mediated through mTOR
and through a second much more potent pathway unique to
muscle, the FoxO3 pathway (Mammucari et al., 2008). This
drastic macroautophagic response is highest in type II fast-
twitch fibers (Li and Goldberg, 1976; Mizushima et al., 2004),
which are the fibers with the highest degree of autophagic vacu-
olation and atrophy in XMEA (Chabrol et al., 2001; Kalimo et al.,
1988; Minassian et al., 2002; Villanova et al., 1995). In fibroblasts
and other cell types we studied, the macroautophagic response
to blocked autophagy is ‘‘excessive’’ (autolysosomes merging
into autophagic vacuoles) in 10% of cells. In muscle, greater
macroautophagic response to the same autophagic block could
underlie the greater autophagic vacuolation (40%–80%) and
defining pathology of the disease.
Do the assembly processes directed by VMA21 in humans
parallel those of Vma21p in yeast? Yeast c, c0, and c00 subunits
compose the rotating cylinder of the V0 sector of the V-ATPase
and are homologous proteins with 32%–56% sequence identity.
Vma21p interacts directly only with c0 and not with other V0
proteins, indicating that its assembling function is mediated
through c0 (Malkus et al., 2004). c0 is altogether absent from
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multicellular organisms (Forgac, 2007). We show that VMA21
interacts directly only with c00, indicating that VMA21 acts via
c00. Human c00 has only 31% amino acid identity and 50% simi-
larity to yeast c0, consistent with the extensive sequence diver-
gence of VMA21 from Vma21p (22% identity). On the other
hand, c00 is strongly conserved from yeast to man (60% identity).
It is possible that human VMA21 is able to rescue yeast vma21D,
despite its great divergence from Vma21p, not by acting through
the substrate of Vma21p, c0, but through the yeast ortholog of its
own substrate, c00.
In yeast, Vma21p accompanies the nascent V-ATPase on
COPII vesicles to the Golgi and returns to the ER on COPI vesi-
cles (Malkus et al., 2004). VMA21 also travels on COPII vesicles,
but it goes only as far as the ERGIC and does not return via COPI.
The systems therefore diverged, and the fate of VMA21 after
ERGIC is unknown. Possibly it simply drifts back to the ER
through the continuousness of ERGIC and ER.
This work describes the clinical outcome at the cusp of toler-
able reduction in V-ATPase, with implications on common
diseases. In malaria, the parasite inserts a V-ATPase into the
erythrocyte membrane, conferring itself optimal pH, and
increased V-ATPase activity is an important component of HIV
infection, osteoporosis, and cancer metastasis (Forgac, 2007).
Our XMEA patients show that the safety margin of reducing
V-ATPase activity in humans is wide, increasing the potential
to utilize bafilomycin-related compounds, or RNAi against
VMA21, as possible therapies.
EXPERIMENTAL PROCEDURES
Mutation Identification
This study was approved by the Research Ethics Board of the Hospital for Sick
Children, and informed consent was obtained from all subjects. Primer pairs to
amplify VMA21 exons and flanking sequences can be found in Table S2. PCR
conditions were as follows: 35 cycles, Taq DNA Polymerase (Fermentas) with
NH4SO4 buffer and 20% betaine for exon 1 and PicoMaxx High-Fidelity PCR
(Stratagene) for exons 2 and 3; denaturation, 94C, 30 s; annealing, 55C,
30 s; elongation, 72C, 40 s.
RT-PCR and Quantitative Real-Time PCR
One microgram total RNA isolated from cultured cells with the RNeasy Mini Kit
(QIAGEN) was converted into cDNA with oligo(dT) primers and SuperScript
First-Strand Synthesis (Invitrogen). RT-PCR was performed with 22 cycles.
A relative standard curve was used to analyze the expression of VMA21 or
minigene constructs normalized to b-actin. A standard curve was prepared
from control lymphoblasts or C2C12 cDNA at 1, 10, 102, 103, and 104 dilution
factors. Each reaction well contained 0.5 ml template cDNA of appropriate
concentration for linear amplification based on the standard curve, 100 ng of
each primer, and 13SYBR Green PCR master mix (Applied Biosystems) to
a final volume of 20 mL. Reactions were carried out with Applied Biosystems
7900HT for 40 cycles (95C, 15 s, 60C, 60 s). PCR product purity was deter-
mined by melting curve analysis. Within each plate, we included triplicates of
each sample. Data were analyzed with SDS2.1 v.2.1.0.3 (Applied Biosystems).
At least three separate experiments per subject were performed. Values
exceeding two standard deviations were excluded.
Complementation Assay
Saccharomyces cerevisiae BY4742 wild-type strain (MATa; his3D1; leu2D0;
lys2D0; ura3D0) and vma21D mutant (BY4742; Mata; his3D1; leu2D0;
lys2D0; ura3D0; YGR105w::kanMX4) were obtained from Euroscarf.
LOC203547 was cloned into yeast expression plasmid pCADNS under alcohol
dehydrogenase (ADH) promoter, terminator, and transformed into BY4742
E
Rand vma21D. Transformants were selected on synthetic complete media
without leucine and assayed for viability on medium containing 10 mM
Cacl2, YPD (pH 7.5; alkaline conditions), and ability to grow on glycerol as
sole carbon source.
V-ATPase Assays
Total protein was measured with the Bradford assay and a bovine serum
albumin (BSA) standard curve. Hydrolysis of ATP by V-ATPase was measured
by the bafilomycin A1-sensitive method. Microsomal pellets were thawed on
ice and suspended in ATPase buffer (10 mM HEPES-Tris [pH 7], 5 mM
MgCl2, 50 mM KCl, 10 mM NaN3, 1 mM levamisole-10 mM NaF, 0.7 mg/ml
leupeptin, 0.7 mg/ml pepstatin A, 48.72 mg/L phenylmethylsulphonyl fluoride
[PMSF]) to a protein concentration of 0.75–1.75 mg/ml (see the Supplemental
Experimental Procedures for subcellular fractionation method). The reaction
mix contained 1 mM ATP substrate, 3 mg total protein samples, 5 mM valinomy-
cin, 5 mM nigericin, 1 mM orthovanadate, 10 mg/mL oligomycin in ATPase
buffer made to 70 ml final volume and incubated in presence and absence of
10 nM bafilomycin for 30 min at 37C. ATP hydrolysis was terminated with
13% SDS and 100 mM ethylenediaminetetraacetic acid (EDTA). Control reac-
tions were done in order to correct any nonenzymatic hydrolysis of ATP or
orthophosphate contamination from reagents by addition of the stop solution
prior to ATP substrate addition. The reaction was initiated by addition of Taus-
sky-Shorr color reagent (0.5% w/v FeSO4, 0.5% w/v ammonium molybdate,
and 0.5 M H2SO4). The reaction was incubated for 20 min at room temperature,
and inorganic phosphate (Pi) was measured by absorbance at 650 nm. A stan-
dard calibration curve was generated with Pi standards (0, 2.5, 5, 10, 25, 50,
100, 150 nmole). Mean values and standard deviation were calculated from
three independent assay repeats done in triplicate.
Determination of Lysosomal pH
Fibroblasts were seeded on 25 mm circular glass coverslips and grown to
confluence in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS; Wisent) at 37C, 5% CO2. At confluence, cells were
washed twice with PBS and serum-starved by addition of DMEM containing
2% FBS for 40 min. Lysosomes were loaded overnight with 0.5 mg/mL
dextran-coupled Oregon Green 514 (Molecular Probes) in DMEM supple-
mented with 10% FBS, chased for 2 hr in DMEM (10% FBS), and washed to
remove residual dextran. Ratiometric fluorescence microscopy was per-
formed with a Leica DMIRB microscope with 1003 (1.4 NA) oil objective.
Fluorescence images were acquired at excitation wavelengths of 440 ± 10 nm
and 490 ± 10 nm. Image acquisition and analysis was performed with Meta-
Morph software (Universal Imaging). Regions of interest (ROIs), representing
late endosomes/lysosomes as resolved by light microscopy, were defined
as areas above a certain fluorescence threshold in the 490 nm excitation
channel. Mean intensity ratio between 490 and 440 nm excitation channels
was calculated for each ROI, and mean ratio weighted by ROI size was then
calculated for each imaged fibroblast. Calibration curves were obtained after
4 min equilibration in nigericin (5 mm) containing MES buffers (30 mM NaCl,
130 mM KCl, 30 mM MgCl2, 25 mM MES, 20 mM glucose) with different pH
values adjusted between pH 3.0 to 7.0. Ratios were converted to pH by using
the calibration curve fitted to a sigmoidal equation. At least six lysosomes
within the same cell were covered, and the experiment was repeated six times
for significance.
Long-Lived Protein Degradation
Confluent cells were labeled with 2 mCi/ml [35S]methionine/[35S]cysteine
Redivue in vitro cell labeling mix for 48 hr at 37C and washed and maintained
in complete medium with excess of unlabeled met and leu for 48 hr. Aliquots of
media and cells taken at different times were precipitated in TCA, and prote-
olyses were measured. Total radioactivity incorporated in cellular proteins
was determined in triplicate samples as the amount of acid-precipitable
radioactivity. Proteolysis was calculated as the percent of acid-precipitable
radioactivity (protein) transformed into acid-soluble radioactivity (amino acids
and peptides) at the different time points analyzed. Values were expressed as
the percent of protein degraded. In separate sets, the above proteolysis exper-
iments were performed in the presence of 15 mM NH4Cl and 100 mM leupeptin
or 10 mM 3-methyladenine (3MA) in the culture medium during the chase. The
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former combination effectively blocks all types of autophagy. Blockage of
macroautophagy was attained with 3MA. The inhibitory effect on the lyso-
somal system was calculated as the decrease in protein degradation sensitive
to NH4Cl, while the inhibitory effect on macroautophagy was determined as
the decrease in protein degradation sensitive to NH4Cl that is also inhibited
by 3MA. Nonmacroautophagy-dependent degradation was calculated as
the percent of protein degradation sensitive to NH4Cl that is not inhibited by
3-methyladenine.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, nine
figures, and two tables and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00155-X.
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